Loading…
Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut
In inflammatory bowel disease, increased production of prostaglandins by cyclooxygenase-2 (COX-2) contributes to bowel dysfunction, inflammatory edema, and hyperemia suggesting that inhibitors of COX-2 may have beneficial effect in gut inflammation. We compared the effects of nimesulide, a preferent...
Saved in:
Published in: | Inflammation 2001-10, Vol.25 (5), p.301-310 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c377t-d9e10e4f26f3ad5360016c3b96098b0c22116bacce724709d1514caddc6770273 |
---|---|
cites | |
container_end_page | 310 |
container_issue | 5 |
container_start_page | 301 |
container_title | Inflammation |
container_volume | 25 |
creator | Kankuri, E Vaali, K Korpela, R Paakkari, I Vapaatalo, H Moilanen, E |
description | In inflammatory bowel disease, increased production of prostaglandins by cyclooxygenase-2 (COX-2) contributes to bowel dysfunction, inflammatory edema, and hyperemia suggesting that inhibitors of COX-2 may have beneficial effect in gut inflammation. We compared the effects of nimesulide, a preferential COX-2 inhibitor, with those of indomethacin, acetylsalicylic acid (ASA), and dexamethasone in a 24-h model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in the rat. TNBS-induced colitis was associated with enhanced COX-2 expression in the gut and increased circulating concentrations of PGE2 metabolite (PGEM). Treatment with nimesulide (10 mg/kg), indomethacin (10 mg/kg), or dexamethasone (1 mg/kg) reduced plasma PGEM concentrations and edema in the inflamed bowel. In addition, nimesulide and dexamethasone treatments decreased neutrophil infiltration into the inflamed colon mucosa. ASA (10 mg/kg) did not have a significant effect on any of these measures of inflammation. None of the studied drugs reduced the size of inflammatory mucosal lesions in the colon. In TNBS-induced acute inflammation of the colon, nimesulide reduced the formation of inflammatory edema, probably by a mechanism related to inhibition of PGE2 production by COX-2 pathway. In addition, nimesulide inhibited neutrophil infiltration into inflamed mucosa mimicking the action of dexamethasone. |
doi_str_mv | 10.1023/a:1012860509440 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72419774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18376501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-d9e10e4f26f3ad5360016c3b96098b0c22116bacce724709d1514caddc6770273</originalsourceid><addsrcrecordid>eNqF0DtPAzEMAOAIgWh5zGwoYmA7sJNLcmGDqjwkRAeKxMQpTXwl6B7lHgP_npMoCwuTLfmzZZuxE4QLBCEv3RUCikyDApumsMOmqIxMhDJ6l01BakiktWbCDrruAwAym8l9NkHMBKTKTNnbvCjI9x1vCu74bPGaCL5pqaCW6j66krv1mPA6VtQNZQzEm5ovn26ek1iHwVPgzg898VgXpasq18exHmvevxNfD_0R2ytc2dHxNh6yl9v5cnafPC7uHmbXj4mXxvRJsIRAaSF0IV1Q49qA2suV1WCzFXghEPXKeU9GpAZsQIWpdyF4bQwIIw_Z-c_cTdt8DtT1eRU7T2XpamqGLh_b0BqT_gsxk0YrwBGe_YEfzdDW4xG5QKWkApON6HSLhlVFId-0sXLtV_77X_kNf7J6Sg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>215535078</pqid></control><display><type>article</type><title>Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut</title><source>Springer Link</source><creator>Kankuri, E ; Vaali, K ; Korpela, R ; Paakkari, I ; Vapaatalo, H ; Moilanen, E</creator><creatorcontrib>Kankuri, E ; Vaali, K ; Korpela, R ; Paakkari, I ; Vapaatalo, H ; Moilanen, E</creatorcontrib><description>In inflammatory bowel disease, increased production of prostaglandins by cyclooxygenase-2 (COX-2) contributes to bowel dysfunction, inflammatory edema, and hyperemia suggesting that inhibitors of COX-2 may have beneficial effect in gut inflammation. We compared the effects of nimesulide, a preferential COX-2 inhibitor, with those of indomethacin, acetylsalicylic acid (ASA), and dexamethasone in a 24-h model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in the rat. TNBS-induced colitis was associated with enhanced COX-2 expression in the gut and increased circulating concentrations of PGE2 metabolite (PGEM). Treatment with nimesulide (10 mg/kg), indomethacin (10 mg/kg), or dexamethasone (1 mg/kg) reduced plasma PGEM concentrations and edema in the inflamed bowel. In addition, nimesulide and dexamethasone treatments decreased neutrophil infiltration into the inflamed colon mucosa. ASA (10 mg/kg) did not have a significant effect on any of these measures of inflammation. None of the studied drugs reduced the size of inflammatory mucosal lesions in the colon. In TNBS-induced acute inflammation of the colon, nimesulide reduced the formation of inflammatory edema, probably by a mechanism related to inhibition of PGE2 production by COX-2 pathway. In addition, nimesulide inhibited neutrophil infiltration into inflamed mucosa mimicking the action of dexamethasone.</description><identifier>ISSN: 0360-3997</identifier><identifier>EISSN: 1573-2576</identifier><identifier>DOI: 10.1023/a:1012860509440</identifier><identifier>PMID: 11820457</identifier><identifier>CODEN: INFLD4</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject><![CDATA[Acute Disease ; Animals ; aspirin ; Aspirin - administration & dosage ; Aspirin - pharmacology ; Colitis - drug therapy ; Cyclooxygenase 2 ; Cyclooxygenase 2 Inhibitors ; Cyclooxygenase Inhibitors - administration & dosage ; Cyclooxygenase Inhibitors - pharmacology ; dexamethasone ; Dexamethasone - administration & dosage ; Dexamethasone - pharmacology ; Dinoprostone - blood ; Dinoprostone - metabolism ; Disease Models, Animal ; Drug Evaluation, Preclinical ; indomethacin ; Indomethacin - administration & dosage ; Indomethacin - pharmacology ; Inflammation - drug therapy ; Inflammation - pathology ; Inflammatory Bowel Diseases - drug therapy ; Isoenzymes - antagonists & inhibitors ; Male ; nimesulide ; Prostaglandin-Endoperoxide Synthases ; Rats ; Rats, Wistar ; Sulfonamides - administration & dosage ; Sulfonamides - pharmacology ; Trinitrobenzenesulfonic Acid]]></subject><ispartof>Inflammation, 2001-10, Vol.25 (5), p.301-310</ispartof><rights>Copyright Kluwer Academic Publishers Oct 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-d9e10e4f26f3ad5360016c3b96098b0c22116bacce724709d1514caddc6770273</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11820457$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kankuri, E</creatorcontrib><creatorcontrib>Vaali, K</creatorcontrib><creatorcontrib>Korpela, R</creatorcontrib><creatorcontrib>Paakkari, I</creatorcontrib><creatorcontrib>Vapaatalo, H</creatorcontrib><creatorcontrib>Moilanen, E</creatorcontrib><title>Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut</title><title>Inflammation</title><addtitle>Inflammation</addtitle><description>In inflammatory bowel disease, increased production of prostaglandins by cyclooxygenase-2 (COX-2) contributes to bowel dysfunction, inflammatory edema, and hyperemia suggesting that inhibitors of COX-2 may have beneficial effect in gut inflammation. We compared the effects of nimesulide, a preferential COX-2 inhibitor, with those of indomethacin, acetylsalicylic acid (ASA), and dexamethasone in a 24-h model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in the rat. TNBS-induced colitis was associated with enhanced COX-2 expression in the gut and increased circulating concentrations of PGE2 metabolite (PGEM). Treatment with nimesulide (10 mg/kg), indomethacin (10 mg/kg), or dexamethasone (1 mg/kg) reduced plasma PGEM concentrations and edema in the inflamed bowel. In addition, nimesulide and dexamethasone treatments decreased neutrophil infiltration into the inflamed colon mucosa. ASA (10 mg/kg) did not have a significant effect on any of these measures of inflammation. None of the studied drugs reduced the size of inflammatory mucosal lesions in the colon. In TNBS-induced acute inflammation of the colon, nimesulide reduced the formation of inflammatory edema, probably by a mechanism related to inhibition of PGE2 production by COX-2 pathway. In addition, nimesulide inhibited neutrophil infiltration into inflamed mucosa mimicking the action of dexamethasone.</description><subject>Acute Disease</subject><subject>Animals</subject><subject>aspirin</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - pharmacology</subject><subject>Colitis - drug therapy</subject><subject>Cyclooxygenase 2</subject><subject>Cyclooxygenase 2 Inhibitors</subject><subject>Cyclooxygenase Inhibitors - administration & dosage</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>dexamethasone</subject><subject>Dexamethasone - administration & dosage</subject><subject>Dexamethasone - pharmacology</subject><subject>Dinoprostone - blood</subject><subject>Dinoprostone - metabolism</subject><subject>Disease Models, Animal</subject><subject>Drug Evaluation, Preclinical</subject><subject>indomethacin</subject><subject>Indomethacin - administration & dosage</subject><subject>Indomethacin - pharmacology</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - pathology</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Isoenzymes - antagonists & inhibitors</subject><subject>Male</subject><subject>nimesulide</subject><subject>Prostaglandin-Endoperoxide Synthases</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - pharmacology</subject><subject>Trinitrobenzenesulfonic Acid</subject><issn>0360-3997</issn><issn>1573-2576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqF0DtPAzEMAOAIgWh5zGwoYmA7sJNLcmGDqjwkRAeKxMQpTXwl6B7lHgP_npMoCwuTLfmzZZuxE4QLBCEv3RUCikyDApumsMOmqIxMhDJ6l01BakiktWbCDrruAwAym8l9NkHMBKTKTNnbvCjI9x1vCu74bPGaCL5pqaCW6j66krv1mPA6VtQNZQzEm5ovn26ek1iHwVPgzg898VgXpasq18exHmvevxNfD_0R2ytc2dHxNh6yl9v5cnafPC7uHmbXj4mXxvRJsIRAaSF0IV1Q49qA2suV1WCzFXghEPXKeU9GpAZsQIWpdyF4bQwIIw_Z-c_cTdt8DtT1eRU7T2XpamqGLh_b0BqT_gsxk0YrwBGe_YEfzdDW4xG5QKWkApON6HSLhlVFId-0sXLtV_77X_kNf7J6Sg</recordid><startdate>20011001</startdate><enddate>20011001</enddate><creator>Kankuri, E</creator><creator>Vaali, K</creator><creator>Korpela, R</creator><creator>Paakkari, I</creator><creator>Vapaatalo, H</creator><creator>Moilanen, E</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20011001</creationdate><title>Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut</title><author>Kankuri, E ; Vaali, K ; Korpela, R ; Paakkari, I ; Vapaatalo, H ; Moilanen, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-d9e10e4f26f3ad5360016c3b96098b0c22116bacce724709d1514caddc6770273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Acute Disease</topic><topic>Animals</topic><topic>aspirin</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - pharmacology</topic><topic>Colitis - drug therapy</topic><topic>Cyclooxygenase 2</topic><topic>Cyclooxygenase 2 Inhibitors</topic><topic>Cyclooxygenase Inhibitors - administration & dosage</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>dexamethasone</topic><topic>Dexamethasone - administration & dosage</topic><topic>Dexamethasone - pharmacology</topic><topic>Dinoprostone - blood</topic><topic>Dinoprostone - metabolism</topic><topic>Disease Models, Animal</topic><topic>Drug Evaluation, Preclinical</topic><topic>indomethacin</topic><topic>Indomethacin - administration & dosage</topic><topic>Indomethacin - pharmacology</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - pathology</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Isoenzymes - antagonists & inhibitors</topic><topic>Male</topic><topic>nimesulide</topic><topic>Prostaglandin-Endoperoxide Synthases</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - pharmacology</topic><topic>Trinitrobenzenesulfonic Acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kankuri, E</creatorcontrib><creatorcontrib>Vaali, K</creatorcontrib><creatorcontrib>Korpela, R</creatorcontrib><creatorcontrib>Paakkari, I</creatorcontrib><creatorcontrib>Vapaatalo, H</creatorcontrib><creatorcontrib>Moilanen, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Inflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kankuri, E</au><au>Vaali, K</au><au>Korpela, R</au><au>Paakkari, I</au><au>Vapaatalo, H</au><au>Moilanen, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut</atitle><jtitle>Inflammation</jtitle><addtitle>Inflammation</addtitle><date>2001-10-01</date><risdate>2001</risdate><volume>25</volume><issue>5</issue><spage>301</spage><epage>310</epage><pages>301-310</pages><issn>0360-3997</issn><eissn>1573-2576</eissn><coden>INFLD4</coden><abstract>In inflammatory bowel disease, increased production of prostaglandins by cyclooxygenase-2 (COX-2) contributes to bowel dysfunction, inflammatory edema, and hyperemia suggesting that inhibitors of COX-2 may have beneficial effect in gut inflammation. We compared the effects of nimesulide, a preferential COX-2 inhibitor, with those of indomethacin, acetylsalicylic acid (ASA), and dexamethasone in a 24-h model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in the rat. TNBS-induced colitis was associated with enhanced COX-2 expression in the gut and increased circulating concentrations of PGE2 metabolite (PGEM). Treatment with nimesulide (10 mg/kg), indomethacin (10 mg/kg), or dexamethasone (1 mg/kg) reduced plasma PGEM concentrations and edema in the inflamed bowel. In addition, nimesulide and dexamethasone treatments decreased neutrophil infiltration into the inflamed colon mucosa. ASA (10 mg/kg) did not have a significant effect on any of these measures of inflammation. None of the studied drugs reduced the size of inflammatory mucosal lesions in the colon. In TNBS-induced acute inflammation of the colon, nimesulide reduced the formation of inflammatory edema, probably by a mechanism related to inhibition of PGE2 production by COX-2 pathway. In addition, nimesulide inhibited neutrophil infiltration into inflamed mucosa mimicking the action of dexamethasone.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>11820457</pmid><doi>10.1023/a:1012860509440</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0360-3997 |
ispartof | Inflammation, 2001-10, Vol.25 (5), p.301-310 |
issn | 0360-3997 1573-2576 |
language | eng |
recordid | cdi_proquest_miscellaneous_72419774 |
source | Springer Link |
subjects | Acute Disease Animals aspirin Aspirin - administration & dosage Aspirin - pharmacology Colitis - drug therapy Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors - administration & dosage Cyclooxygenase Inhibitors - pharmacology dexamethasone Dexamethasone - administration & dosage Dexamethasone - pharmacology Dinoprostone - blood Dinoprostone - metabolism Disease Models, Animal Drug Evaluation, Preclinical indomethacin Indomethacin - administration & dosage Indomethacin - pharmacology Inflammation - drug therapy Inflammation - pathology Inflammatory Bowel Diseases - drug therapy Isoenzymes - antagonists & inhibitors Male nimesulide Prostaglandin-Endoperoxide Synthases Rats Rats, Wistar Sulfonamides - administration & dosage Sulfonamides - pharmacology Trinitrobenzenesulfonic Acid |
title | Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T01%3A13%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20a%20COX-2%20preferential%20agent%20nimesulide%20on%20TNBS-induced%20acute%20inflammation%20in%20the%20gut&rft.jtitle=Inflammation&rft.au=Kankuri,%20E&rft.date=2001-10-01&rft.volume=25&rft.issue=5&rft.spage=301&rft.epage=310&rft.pages=301-310&rft.issn=0360-3997&rft.eissn=1573-2576&rft.coden=INFLD4&rft_id=info:doi/10.1023/a:1012860509440&rft_dat=%3Cproquest_pubme%3E18376501%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c377t-d9e10e4f26f3ad5360016c3b96098b0c22116bacce724709d1514caddc6770273%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=215535078&rft_id=info:pmid/11820457&rfr_iscdi=true |